1. Generation and validation of a mouse model of the phospholamban p.Arg14del mutation

   Eijgenraam, T., Sillje, H. & de Boer, R., 2018, In : European Journal of Heart Failure. 20, Suppl. S1, p. 197 1 p., 854.

   Research output: Contribution to journal › Meeting Abstract › Academic

2. A novel phospholamban p.Arg14del cardiomyopathy mouse line treated with heart failure medication

   Eijgenraam, T. R., Schouten, E. M., Gehlken, A. C. D. I., Dokter, M. M., Sillje, H. H. W. & De Boer, R. A., May-2019, In : European Journal of Heart Failure. 21, Suppl. S1, p. 477 1 p., P1879.

   Research output: Contribution to journal › Meeting Abstract › Academic

3. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy

   Eijgenraam, T. R., Boukens, B. J., Boogerd, C. J., Schouten, E. M., van de Kolk, C. W. A., Stege, N. M., Te Rijdt, W. P., Hoorntje, E. T., van der Zwaag, P. A., van Rooij, E., van Tintelen, J. P., van den Berg, M. P., van der Meer, P., van der Velden, J., Silljé, H. H. W. & de Boer, R. A., 17-Jun-2020, In : Scientific Reports. 10, 1, 13 p., 9819.

   Research output: Contribution to journal › Article › Academic › peer-review

4. Current understanding of fibrosis in genetic cardiomyopathies

   Eijgenraam, T. R., Silljé, H. H. W. & de Boer, R. A., 23-Sep-2019, In : TRENDS IN CARDIOVASCULAR MEDICINE. 9 p.

   Research output: Contribution to journal › Review article › Academic › peer-review

5. A novel method optimizing the normalization of cardiac parameters in small animal models: the importance of dimensional indexing

   Hagdorn, Q. A. J., Bossers, G., Koop, A-M. C., Piek, A., Eijgenraam, T. R., van der Feen, D. E., Sillje, H. H. W., de Boer, R. A. & Berger, R. M. F., Jun-2019, In : AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 136, 6, 6 p., H1552-H1557.

   Research output: Contribution to journal › Article › Academic › peer-review

View all (6) »